Exemestane is a synthetic steroidal aromatase inhibitor, primarily used in the management of hormone-sensitive breast cancer. It is chemically classified as a steroidal agent and is marketed under the trade name Aromasin. Exemestane is distinct from non-steroidal aromatase inhibitors due to its steroidal structure, which may confer additional benefits in terms of bone and lipid metabolism. Researchers have extensively studied exemestane for its role in reducing estrogen production, which is crucial in the treatment of estrogen receptor-positive breast cancer. Exemestane is primarily used in postmenopausal women with advanced breast cancer, where it has shown efficacy as a second- or third-line treatment option. It is also used in premenopausal women in combination with ovarian suppression therapy. The mechanism of action of exemestane involves irreversible binding to the aromatase enzyme, leading to a significant reduction in circulating estrogen levels. This reduction in estrogen is achieved through the inactivation of peripheral aromatase activity, which is responsible for the conversion of androgens to estrogens. Pharmacokinetically, exemestane is administered orally, with a recommended dose of 25 mg per day. It has a relatively long half-life, allowing for once-daily dosing. Exemestane is metabolized primarily in the liver and has a bioavailability that is influenced by first-pass metabolism. Clinically, exemestane is approved for use in hormone receptor-positive breast cancer and is considered a standard treatment option in various guidelines. It is generally well-tolerated, with common side effects including hot flushes, nausea, and fatigue. Exemestane is available by prescription and is regulated by health authorities in various countries.